Streetbeat News

Analyst Ratings

FIVN

Piper Sandler analyst James Fish has maintained an Overweight rating on Five9 (NASDAQ:FIVN) and increased the price target from $84 to $86.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:48 pm

FFNW

Piper Sandler analyst Andrew Liesch has maintained an Overweight rating on First Financial Northwest (NASDAQ: FFNW) and increased the price target from $14 to $23.5.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:46 pm

ENPH

Piper Sandler analyst Kashy Harrison has maintained a Neutral rating on Enphase Energy (NASDAQ:ENPH) but has reduced the price target from $120 to $117.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:39 pm

COO

Piper Sandler analyst Jason Bednar has maintained an Overweight rating on Cooper Companies (NASDAQ:COO) and increased the price target from $430 to $440.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:31 pm

AMD

INTC

NVDA

QCOM

Qualcomm Inc (QCOM) shares are trading higher pre-market on Jan. 12 after Citigroup upgraded the stock from Neutral to Buy, raising the target price to $160 from $110. The upgrade is based on expectations of a handset market recovery, which could benefit Qualcomm's revenue and margins. Qualcomm's recent performance shows a 29.94% rise in the past three months and a technical 'golden cross' in December 2023. Qualcomm is set to release its Q1 earnings report on Jan. 31. Meanwhile, peers NVIDIA (NVDA), AMD (AMD), and Intel (INTC) traded lower.

Portfolio Pulse from Surbhi Jain

January 12, 2024 | 3:28 pm

DOCU

RBC Capital analyst Rishi Jaluria has reiterated a 'Sector Perform' rating on DocuSign (NASDAQ:DOCU), maintaining a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:19 pm

REGN

VTRS

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) won a lawsuit against Viatris Inc (NASDAQ:VTRS) over its Eylea patent, which, along with strong Dupixent sales and potential in the COPD market, has led BMO Capital Markets analyst Brian Abrahams to upgrade REGN from Sector Perform to Outperform with a new price target of $1,076. Abrahams anticipates Dupixent sales to reach $14.0 billion in 2024, surpassing consensus estimates. The recent patent win for Eylea and promising oncology programs like linvo and fianlimab are also positive indicators for REGN's stock. Following the news, REGN shares rose by 1.50% to $929.68.

Portfolio Pulse from Priya Nigam

January 12, 2024 | 3:18 pm

CHK

Chesapeake Energy's stock (CHK) is trading higher following upgrades to bullish ratings by Citigroup and Mizuho. The rise is also in line with a broader increase in energy stocks, which is attributed to supply uncertainty stemming from Middle East conflict.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:15 pm

ACI

RBC Capital analyst Steven Shemesh has reiterated an Outperform rating on Albertsons Companies (NYSE:ACI) and maintained a price target of $24.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:15 pm

TWLO

Twilio Inc. shares have risen following an upgrade by Piper Sandler from Neutral to Overweight, with an increased price target from $75 to $82.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:06 pm